drugset / Trial / NCT05347576

A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions

NCT05347576

Phase 1 Completed 31 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions

Timeline

Start
2022-04-21
Primary completion
2022-05-02
Completion
2022-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-393(2) Unknown Oral
Subject D029 Unknown Oral
Subject D150 Unknown Oral
Subject D759 Unknown Oral
Subject Lobeglitazone Small molecule Oral